The use of investigator-assigned subjective or judgmental efficacy and toxicity reporting in early phase clinical trials of lung cancer treatments

Investigator-assigned Subjective or Judgmental Efficacy and Toxicity (ISJET) reporting represents language used to contextualize efficacy or toxicity data in clinical trials that may be inappropriate or misleading. In addition, pooling of grade 1 and 2 adverse events (AEs) may reflect a practice bas...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of thoracic oncology 2024-12
Hauptverfasser:	Phillips, William J., Watson, Alexander S., Camidge, D Ross
Format:	Artikel
Sprache:	eng
Schlagworte:	adverse event conferences early phase clinical trials lung cancer Toxicity reporting
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!